 Amrut Ambardekar
Concepts (422)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 37 | 2024 | 529 | 8.490 |
Why?
| | Heart Failure | 51 | 2024 | 2145 | 6.370 |
Why?
| | Heart Transplantation | 24 | 2024 | 713 | 4.990 |
Why?
| | Amyloidosis | 4 | 2023 | 39 | 1.850 |
Why?
| | Cardiomyopathies | 9 | 2025 | 334 | 1.780 |
Why?
| | Heart Ventricles | 9 | 2020 | 779 | 1.620 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 373 | 1.130 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 387 | 1.080 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 129 | 1.000 |
Why?
| | Myocardium | 10 | 2023 | 982 | 0.960 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 312 | 0.880 |
Why?
| | Myocytes, Cardiac | 11 | 2023 | 484 | 0.860 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 226 | 0.860 |
Why?
| | Humans | 101 | 2025 | 129705 | 0.840 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 295 | 0.830 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.800 |
Why?
| | Assisted Circulation | 2 | 2021 | 25 | 0.780 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.770 |
Why?
| | Transplant Recipients | 4 | 2021 | 157 | 0.770 |
Why?
| | Fibrosis | 5 | 2022 | 521 | 0.750 |
Why?
| | Echocardiography | 7 | 2017 | 635 | 0.750 |
Why?
| | Hemodynamics | 7 | 2023 | 1097 | 0.730 |
Why?
| | Stroke Volume | 9 | 2024 | 588 | 0.730 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 62 | 0.710 |
Why?
| | Giant Cells | 1 | 2020 | 21 | 0.710 |
Why?
| | Vascular Stiffness | 2 | 2017 | 480 | 0.710 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 706 | 0.710 |
Why?
| | Arteries | 1 | 2022 | 268 | 0.690 |
Why?
| | Aortic Diseases | 1 | 2021 | 112 | 0.690 |
Why?
| | Heart Neoplasms | 1 | 2020 | 51 | 0.680 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 527 | 0.670 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 75 | 0.670 |
Why?
| | Coronary Vessels | 2 | 2018 | 252 | 0.650 |
Why?
| | Myocarditis | 1 | 2020 | 101 | 0.640 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 274 | 0.640 |
Why?
| | Middle Aged | 36 | 2025 | 31103 | 0.630 |
Why?
| | Brugada Syndrome | 2 | 2009 | 9 | 0.610 |
Why?
| | Graft Rejection | 3 | 2021 | 569 | 0.610 |
Why?
| | Myocardial Contraction | 4 | 2020 | 336 | 0.600 |
Why?
| | Heart | 6 | 2023 | 650 | 0.580 |
Why?
| | Bariatric Surgery | 1 | 2021 | 190 | 0.570 |
Why?
| | Extracellular Matrix | 1 | 2021 | 493 | 0.570 |
Why?
| | Male | 48 | 2025 | 63544 | 0.560 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 255 | 0.540 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 255 | 0.540 |
Why?
| | Female | 48 | 2025 | 68561 | 0.520 |
Why?
| | Cryosurgery | 1 | 2016 | 54 | 0.490 |
Why?
| | Thrombosis | 2 | 2016 | 331 | 0.490 |
Why?
| | Amyloid Neuropathies, Familial | 2 | 2025 | 13 | 0.480 |
Why?
| | Heart Rate | 2 | 2021 | 808 | 0.480 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 249 | 0.460 |
Why?
| | Aged | 22 | 2025 | 22113 | 0.450 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 167 | 0.450 |
Why?
| | Blood Pressure | 5 | 2022 | 1747 | 0.430 |
Why?
| | Electrocardiography | 4 | 2020 | 607 | 0.430 |
Why?
| | Marijuana Abuse | 1 | 2016 | 230 | 0.430 |
Why?
| | Treatment Outcome | 13 | 2024 | 10299 | 0.410 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 260 | 0.410 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 537 | 0.400 |
Why?
| | Myofibrils | 3 | 2022 | 50 | 0.400 |
Why?
| | Patient-Centered Care | 2 | 2021 | 505 | 0.390 |
Why?
| | Guideline Adherence | 3 | 2011 | 531 | 0.370 |
Why?
| | Adult | 21 | 2023 | 35595 | 0.360 |
Why?
| | Patient Compliance | 2 | 2017 | 566 | 0.350 |
Why?
| | Prealbumin | 3 | 2025 | 27 | 0.350 |
Why?
| | Cardiology | 2 | 2023 | 282 | 0.340 |
Why?
| | Recovery of Function | 2 | 2011 | 643 | 0.340 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 15 | 0.340 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 175 | 0.330 |
Why?
| | Hospitals, Rural | 1 | 2009 | 35 | 0.330 |
Why?
| | Risk Assessment | 6 | 2021 | 3297 | 0.330 |
Why?
| | Calcium | 4 | 2023 | 1182 | 0.330 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 58 | 0.330 |
Why?
| | Sarcomeres | 3 | 2022 | 92 | 0.330 |
Why?
| | Baroreflex | 2 | 2021 | 61 | 0.320 |
Why?
| | Cardiac Output | 3 | 2023 | 158 | 0.320 |
Why?
| | Cannabis | 1 | 2016 | 439 | 0.320 |
Why?
| | Safety | 1 | 2011 | 328 | 0.320 |
Why?
| | Automobile Driving | 1 | 2011 | 145 | 0.320 |
Why?
| | Hospitals, Urban | 1 | 2009 | 136 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2424 | 0.320 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 83 | 0.310 |
Why?
| | Pulsatile Flow | 2 | 2018 | 61 | 0.300 |
Why?
| | Registries | 6 | 2021 | 2008 | 0.300 |
Why?
| | Mastitis | 1 | 2007 | 4 | 0.290 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 46 | 0.290 |
Why?
| | Vascular Remodeling | 2 | 2021 | 186 | 0.290 |
Why?
| | Counseling | 1 | 2011 | 384 | 0.290 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.290 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1442 | 0.280 |
Why?
| | Length of Stay | 2 | 2009 | 1133 | 0.280 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 321 | 0.280 |
Why?
| | Coronary Disease | 1 | 2009 | 389 | 0.280 |
Why?
| | Environment | 1 | 2009 | 348 | 0.270 |
Why?
| | Prospective Studies | 10 | 2021 | 7130 | 0.270 |
Why?
| | Retrospective Studies | 13 | 2023 | 14669 | 0.260 |
Why?
| | Diastole | 2 | 2018 | 152 | 0.260 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4939 | 0.250 |
Why?
| | HIV Infections | 1 | 2020 | 2744 | 0.250 |
Why?
| | Inpatients | 1 | 2009 | 456 | 0.250 |
Why?
| | Troponin I | 2 | 2019 | 75 | 0.240 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 25 | 0.240 |
Why?
| | Quality of Health Care | 1 | 2009 | 616 | 0.230 |
Why?
| | Perioperative Care | 2 | 2017 | 151 | 0.220 |
Why?
| | Quality of Life | 6 | 2024 | 2712 | 0.220 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.210 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 40 | 0.210 |
Why?
| | Preoperative Care | 2 | 2017 | 345 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2071 | 0.200 |
Why?
| | Patient Transfer | 2 | 2019 | 164 | 0.200 |
Why?
| | MicroRNAs | 2 | 2022 | 671 | 0.200 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 33 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 39 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 95 | 0.200 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 423 | 0.200 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.200 |
Why?
| | Hospitalization | 4 | 2024 | 2091 | 0.200 |
Why?
| | Cohort Studies | 6 | 2023 | 5410 | 0.200 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.200 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 11 | 0.190 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 10 | 0.190 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 15 | 0.190 |
Why?
| | Succinic Acid | 2 | 2019 | 38 | 0.190 |
Why?
| | Triage | 1 | 2024 | 219 | 0.190 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 128 | 0.190 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.190 |
Why?
| | Leukopenia | 1 | 2021 | 28 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 138 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 213 | 0.180 |
Why?
| | Prognosis | 5 | 2025 | 3801 | 0.180 |
Why?
| | Carrier Proteins | 2 | 2022 | 730 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2021 | 21 | 0.180 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 95 | 0.180 |
Why?
| | Muscle Proteins | 1 | 2022 | 224 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2022 | 3363 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2022 | 215 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1240 | 0.170 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1032 | 0.170 |
Why?
| | Cell Adhesion | 2 | 2018 | 452 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1700 | 0.170 |
Why?
| | Disease Progression | 2 | 2018 | 2612 | 0.160 |
Why?
| | HIV | 1 | 2020 | 224 | 0.160 |
Why?
| | Terminology as Topic | 1 | 2020 | 205 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 126 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 271 | 0.160 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2783 | 0.160 |
Why?
| | Consensus | 4 | 2023 | 646 | 0.150 |
Why?
| | United States | 9 | 2023 | 14078 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 355 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2670 | 0.150 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 311 | 0.150 |
Why?
| | Exercise Test | 4 | 2023 | 620 | 0.150 |
Why?
| | Mice | 11 | 2023 | 16585 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 222 | 0.150 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 245 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 198 | 0.150 |
Why?
| | Aortic Valve | 1 | 2022 | 425 | 0.150 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.150 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 181 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 234 | 0.140 |
Why?
| | Recurrence | 1 | 2020 | 1016 | 0.140 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 10 | 0.140 |
Why?
| | Mutation | 2 | 2018 | 3674 | 0.140 |
Why?
| | Pilot Projects | 3 | 2019 | 1567 | 0.140 |
Why?
| | Anesthetics | 1 | 2017 | 58 | 0.140 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 224 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 148 | 0.140 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 17 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.130 |
Why?
| | Transcriptome | 2 | 2020 | 872 | 0.130 |
Why?
| | Brain | 2 | 2018 | 2596 | 0.130 |
Why?
| | ErbB Receptors | 1 | 2020 | 601 | 0.130 |
Why?
| | Down-Regulation | 2 | 2016 | 637 | 0.130 |
Why?
| | Time Factors | 5 | 2024 | 6593 | 0.130 |
Why?
| | Transition to Adult Care | 1 | 2017 | 74 | 0.130 |
Why?
| | Animals | 14 | 2023 | 34733 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 374 | 0.130 |
Why?
| | Polypharmacy | 1 | 2017 | 83 | 0.130 |
Why?
| | Histone Deacetylases | 1 | 2018 | 211 | 0.130 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 247 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2021 | 1858 | 0.130 |
Why?
| | Eligibility Determination | 1 | 2016 | 64 | 0.130 |
Why?
| | Prosthesis Design | 3 | 2014 | 322 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 67 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1008 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 509 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 395 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 69 | 0.130 |
Why?
| | Drug Interactions | 1 | 2017 | 371 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 47 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1696 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 284 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 709 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 248 | 0.120 |
Why?
| | Tacrolimus | 1 | 2016 | 146 | 0.120 |
Why?
| | Phosphorylation | 3 | 2019 | 1687 | 0.120 |
Why?
| | Hospital Mortality | 2 | 2009 | 858 | 0.120 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1227 | 0.120 |
Why?
| | Viscosity | 1 | 2015 | 90 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2016 | 116 | 0.120 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 55 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1206 | 0.120 |
Why?
| | Health Status | 1 | 2019 | 751 | 0.120 |
Why?
| | Elastic Modulus | 1 | 2015 | 123 | 0.120 |
Why?
| | Biomarkers | 3 | 2023 | 3893 | 0.110 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 157 | 0.110 |
Why?
| | Rats | 5 | 2022 | 5244 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 695 | 0.110 |
Why?
| | Attitude to Health | 1 | 2017 | 430 | 0.110 |
Why?
| | Hip Prosthesis | 1 | 2014 | 34 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2018 | 392 | 0.110 |
Why?
| | Systole | 1 | 2014 | 190 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2017 | 511 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1409 | 0.110 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 61 | 0.110 |
Why?
| | Vaccination | 1 | 2022 | 1362 | 0.110 |
Why?
| | Patient Selection | 2 | 2017 | 685 | 0.110 |
Why?
| | Incidence | 3 | 2019 | 2658 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2014 | 120 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 814 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 228 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1113 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 241 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 745 | 0.100 |
Why?
| | Young Adult | 6 | 2019 | 12363 | 0.100 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 31 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2016 | 644 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1092 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3054 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1098 | 0.090 |
Why?
| | Risk Factors | 4 | 2020 | 9832 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 863 | 0.090 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 82 | 0.090 |
Why?
| | Decision Making | 1 | 2017 | 842 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 162 | 0.090 |
Why?
| | Connectin | 2 | 2022 | 32 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2522 | 0.090 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 126 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2020 | 76 | 0.090 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 176 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1111 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1849 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 21 | 0.080 |
Why?
| | Anticoagulants | 1 | 2014 | 623 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 207 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 145 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 1545 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 71 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1406 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 4058 | 0.080 |
Why?
| | Exercise | 1 | 2020 | 1931 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 320 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1291 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4016 | 0.080 |
Why?
| | Ultrasonography | 1 | 2012 | 729 | 0.080 |
Why?
| | Europe | 2 | 2020 | 370 | 0.080 |
Why?
| | Transcription Factors | 1 | 2016 | 1636 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 138 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 343 | 0.070 |
Why?
| | Body Temperature | 1 | 2007 | 216 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 731 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 414 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 583 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 279 | 0.070 |
Why?
| | Delivery of Health Care | 2 | 2023 | 904 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 458 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2272 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 367 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2022 | 2778 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 259 | 0.060 |
Why?
| | Benzoxazoles | 1 | 2024 | 20 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1529 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 438 | 0.060 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2024 | 102 | 0.060 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 44 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1836 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 53 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2008 | 0.050 |
Why?
| | Travel | 1 | 2023 | 123 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5050 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 19 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1287 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 95 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 96 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 154 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 50 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 179 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 43 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2314 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 149 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4863 | 0.050 |
Why?
| | Adolescent | 4 | 2019 | 20355 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 319 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.050 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 143 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 27 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 2557 | 0.050 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 12 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 59 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 369 | 0.040 |
Why?
| | Graft Survival | 1 | 2023 | 525 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 172 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1721 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 120 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2022 | 5279 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 169 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 1894 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 673 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 396 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 159 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 271 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 61 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 105 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 44 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 474 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 170 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 28 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 218 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 579 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2024 | 7074 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 180 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 880 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 420 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 186 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 84 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 227 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 1056 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 482 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 8 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 342 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 416 | 0.040 |
Why?
| | Zebrafish | 1 | 2022 | 448 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 680 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 88 | 0.040 |
Why?
| | Fibroblasts | 1 | 2022 | 946 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 171 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 433 | 0.040 |
Why?
| | Lysine | 1 | 2019 | 266 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 133 | 0.040 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 11 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 76 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 849 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 359 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5396 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 26 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 10 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 383 | 0.030 |
Why?
| | Papio | 1 | 2017 | 97 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 399 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 144 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 391 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 402 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 22 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 167 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 63 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 206 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 596 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 819 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 731 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 137 | 0.030 |
Why?
| | Actins | 1 | 2018 | 403 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 235 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3351 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 327 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 784 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 876 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 159 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1297 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 431 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2768 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 484 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1981 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 26 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 676 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2075 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 52 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 555 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 463 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 1130 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1047 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1707 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 150 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 988 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 798 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2016 | 315 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 10565 | 0.030 |
Why?
| | Creatine | 1 | 2013 | 55 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 252 | 0.030 |
Why?
| | Glutamine | 1 | 2013 | 94 | 0.030 |
Why?
| | Chromatin | 1 | 2016 | 470 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1632 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 577 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 392 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 134 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1290 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2705 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 239 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 576 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 320 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3063 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 299 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 920 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 862 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1952 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 325 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3145 | 0.020 |
Why?
| | Child | 2 | 2019 | 20963 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 977 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 456 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 684 | 0.020 |
Why?
| | Infant | 1 | 2015 | 9097 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1026 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 321 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|